Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-11-18

FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)

View source ↗

Summary

FDA granted Hospira, Inc. a supplemental approval for ondansetron (ONDANSETRON) under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ondansetron (ondansetron)

Snippet

SUPPL AP for ONDANSETRON (ONDANSETRON)